| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total other income (expense), net | 716 | 834 | 948 | 746 |
| Net loss | -11,258 | -13,943 | -13,434 | -11,855 |
| Preferred stock dividend payable on series a convertible preferred stock | 6 | 6 | 6 | 6 |
| Net loss attributable to common stockholders | -11,264 | -13,949 | -13,440 | -11,861 |
| Earnings per share, basic | -0.17 | -0.21 | -0.2 | -0.25 |
| Earnings per share, diluted | -0.17 | -0.21 | -0.2 | -0.25 |
| Weighted average number of shares outstanding, basic | 66,879,000 | 66,526,000 | 66,524,000 | 46,865,000 |
| Weighted average number of shares outstanding, diluted | 66,879,000 | 66,526,000 | 66,524,000 | 46,865,000 |
Cardiff Oncology, Inc. (CRDF)
Cardiff Oncology, Inc. (CRDF)